Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information (Tables)

v3.22.0.1
Note 13 - Segment Information (Tables)
6 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

Quarter Ended

   

Six Months Ended

 
   

December 31,

   

December 31,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales:

                               

Protein Sciences

  $ 204,971     $ 172,179     $ 402,156     $ 326,625  

Diagnostics and Genomics

    64,527       52,469       125,512       102,595  

Intersegment

    (222 )     (395

)

    (673 )     (768

)

Consolidated net sales

  $ 269,276     $ 224,253     $ 526,995     $ 428,452  

Operating income:

                               

Protein Sciences

  $ 93,281     $ 80,453     $ 183,381     $ 150,803  

Diagnostics and Genomics

    10,880       8,107       18,344       16,781  

Segment operating income

  $ 104,161     $ 88,560     $ 201,725     $ 167,584  

Costs recognized on sale of acquired inventory

    (84 )     (23

)

    (1,595 )     (23

)

Amortization of acquisition related intangible assets

    (18,380 )     (15,027

)

    (36,769 )     (30,528

)

Impact of partially owned consolidated subsidiaries(1)

    (1,004 )     (207 )     (2,567 )     (207 )

Acquisition related expenses

    13,262       (4,421

)

    15,618       (4,558

)

Eminence impairment     (18,715 )     -       (18,715 )     -  

Stock based compensation, inclusive of employer taxes

    (14,815 )     (16,225

)

    (28,675 )     (29,557

)

Restructuring costs

    (743 )     (142 )     (1,928 )     (142

)

Corporate general, selling, and administrative expenses

    (1,334 )     (1,520

)

    (1,524 )     (2,482

)

Consolidated operating income

  $ 62,348     $ 50,995     $ 125,570     $ 100,087